Company intelligence / Profile preview

Hamamatsu Photonics

Hamamatsu, Shizuoka, Japanhamamatsu.com ↗

Ownership: Private
Employees: ~5000
Development stage: Commercial

Overview

No clinical results as the company does not develop drugs or direct therapies. Its photonic devices have enabled major scientific discoveries such as the confirmation of the Higgs boson and neutrino mass. Products widely adopted in medical imaging, analytical instruments, and advanced research applications globally. Recent partnership with PredxBio to integrate spatial biomarker analytics with advanced imaging for immuno-oncology research. Launched new InGaAs photodiodes series and mid-infrared detector modules in 2025.

Therapeutic areas: OncologyRare DiseasesOther
Modalities: DeviceImaging sensorLight source technology
Industry: Medical Imaging

Partnerships

PredxBio – partnership on spatial biomarker analytics for immuno-oncology research announced April 2025

Beyond the preview

Go deeper on Hamamatsu Photonics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hamamatsu Photonics.